Posts by Marlene P. Freeman, MD
-
Clinicians Should Consider Reproductive Health When Treating Women with Psychiatric Illness
Conflicting approaches to care for women with psychiatric illnesses can endanger women before and during pregnancy. Marlene Freeman, MD, advocates for clinicians to help patients in pregnancy by establishing a common understanding of the benefits and risks of psychiatric medications.
-
Women with Major Depression During Pregnancy Have High Rates of Recurrence During Their Child's Formative Years
Depression during pregnancy is highly likely to recur after delivery, Mass General researchers have determined. The finding implies that maternal depression is a major confounder when assessing the influence of prenatal antidepressant exposure on child neurodevelopment.
Biography
Marlene P. Freeman, MD is the Associate Medical Director, Clinical Trials Network & Institute;Director of Clinical Services, Perinatal and Reproductive Psychiatry Program, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School.
Dr. Freeman completed medical school at Northwestern University Medical School. She completed residency at the Harvard Longwood Psychiatry Residency Program and a research fellowship in the Biological Psychiatry Program at the University of Cincinnati College of Medicine.
Her research and clinical expertise is in the areas of mood disorders and women's mental health. She established and directed Women's Mental Health Programs at the University of Arizona and the University of Texas Southwestern Medical Center.
As a researcher in perinatal psychiatry, she has specific experience working with vulnerable populations. She also has extensive experience in the area of safety, recruitment, and retention of women in clinical trials. She is Vice Editor-in-Chief for The Journal of Clinical Psychiatry.
She is a Distinguished Fellow of the American Psychiatric Association (APA), and chaired the APA Task Force on Complementary and Alternative Medicine, subcommittee on Omega-3 Fatty Acids in Psychiatry, and was a member of the APA's workgroup on Major Depressive Disorder treatment guidelines.
She is on the Board of Directors of the American Society of Clinical Psychopharmacology (ASCP) and Postpartum Progress, Inc, and is an Associate Member of the American College of Neuropsychopharmacology (ACNP). She chairs the Membership Advisory Task Force and serves on the Women's Task Force for ACNP.
